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edu.au or barres@sund.ku.dkAbstractErythropoietin (EPO) ameliorates glucose metabolism through mechanisms not fully
understood. In this study, we investigated the effect of EPO on glucose metabolism and insulin
signaling in skeletal muscle. A 2-week EPO treatment of rats fed with a high-fat diet (HFD)
improved fasting glucose levels and glucose tolerance, without altering total body weight
or retroperitoneal fat mass. Concomitantly, EPO partially rescued insulin-stimulated AKT
activation, reduced markers of oxidative stress, and restored heat-shock protein 72 expression
in soleus muscles from HFD-fed rats. Incubation of skeletal muscle cell cultures with EPO failed
to induce AKT phosphorylation and had no effect on glucose uptake or glycogen synthesis.
We found that the EPO receptor gene was expressed in myotubes, but was undetectable in
soleus. Together, our results indicate that EPO treatment improves glucose tolerance but
does not directly activate the phosphorylation of AKT in muscle cells. We propose that
the reduced systemic inflammation or oxidative stress that we observed after treatment
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(2015) 225, 77–88IntroductionErythropoietin (EPO) is a glycoprotein synthesized by
the kidney and plays a role in the regulation of red
blood cell growth and survival. EPO, classically used forthe treatment of anemia in chronic kidney disease, has
recently emerged as a regulator involved in glucose
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225 :2 78with end-stage renal disease (ESRD) indicated that EPO not
only treated anemia but also improved insulin sensitivity
(Borissova et al. 1993, Mak 1996). Results of other clinical
studies of ESRD patients indicated that EPO treatment could
improve fasting plasma insulin level (Tuzcu et al. 2004,
Khedr et al. 2009) and control blood glucose (Spaia et al.
2000, Khedr et al. 2009). The results of these studies have
indicated that improvements in glucose homeostasis and
insulin sensitivity occurred before, or independently of
increased hematocrit, indicating a metabolic role for EPO
that is dissociated from hematopoiesis (Spaia et al. 2000).
Animal models of long-term exposure to EPO showed clear
positive effects on glucose metabolism. Transgenic mice
constitutively overexpressing EPO displayed decreased body
weight and improved glucose metabolism as compared with
WT litter mates (Katz et al. 2010). Conversely, long-term
exposure to EPO could prevent diet-induced obesity
(Hojman et al. 2009). While a role of EPO in mediating
muscle anabolism has been suggested, evidence that EPO
directly targets skeletal muscle is still lacking.
Results of cell culture experiments indicated that EPO
has the potential to directly target metabolic cells. Acute
treatment with EPO protects pancreatic cells against the
combined action of pro-apoptotic cytokines interleukin 1
(IL1b) tumor nexcosis factor alpha (TNFa), and interferon
gamma (IFNg), suggesting indicative of its cytoprotective
role (Maiese et al. 2005). In cultured adipocytes, EPO
prevented dexamethasone-induced decrease in glucose
uptake (Mikola´s et al. 2012, Pan et al. 2013).
In this study, we investigated theeffect ofboth acute and
chronic EPO treatment on whole-body glucose metabolism
and activation of the insulin signaling pathway in skeletal
muscle.WefoundthatEPOamelioratesdiet-inducedglucose
intolerance and insulin signaling. We also show that EPO
does not target the skeletal muscle cell indicating an indirect
action through the improvement of several systemic factors
known to be beneficial for whole-body glucose metabolism.Materials and methods
Chemicals, ELISA kits, and antibodies
Palmiticacidendotoxin-freecell culture grade, anti-protease
cocktail (P8340), andBSA (cell culturegrade)werepurchased
from Sigma–Aldrich. Fetal bovine serum (FBS), minimum
essential media alpha (MEMa), and penicillin/streptomycin
(P/S) antibiotic cocktail (15070-063) were from purchased
Gibco. The experiments were conducted with human
recombinant EPO (Janssen Cilag, Sydney, NSW, Australia).
Primary antibodies were from Stressgen (heat-shock proteinhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
 2015 The authors
Printed in Great Britain72 (HSP72), SPA-810, 1/2000, Victoria, BC, Canada) or
Cell Signaling (AKT (9272), P-AKT(Ser473) (9271), Danvers,
MA, USA), and secondary antibodies were purchased from
Sigma–Aldrich (sheep anti-mouse, A5906) or Cell Signaling
(goat anti-rabbit, 7074). Serum insulin and TNFa were
measured using rat ultrasensitive ELISA Kits (Alpco, Labora-
tory Diagnostics (Caringbah, NSW, Australia) and R&D
Systems, Inc. (Minneapolis, MN, USA) respectively). Trigly-
cerides (TGs) and cholesterol were measured using Thermo
Scientific (Waltham, MA, USA) and Stanbio Kits respectively
(Boerne,TX,USA). Bloodglucose levelsweremeasured using
an AcuCheck II glucometer (Roche, Castle Hill, NSW).
D-[U-14C]-glucose and scintillation liquid (Ultima gold) were
obtained from Perkin Elmer (Waltham, MA, USA).Cell culture
L6 and 3T3L1 cells were obtained from Lonza (Stockholm,
Sweden). Human muscle primary cell cultures were estab-
lished from muscle biopsies collected from male partici-
pants. The protocol was approved by the Local Ethics
Committee (03/10/GESE,Montpellier, France) and informed
and written consent was obtained from all participants.
Myoblasts isolation, purification, and culture were
performed as described previously (Barro et al. 2010). Muscle
cells were grown in medium containing MEMa supple-
mented with 10% FBS and50 mg/mlP/S at5%CO2 and37 8C.
Once at confluence, cells were grown in MEMa, 2% FBS, and
50 mg/ml P/S. All experiments were conducted at the
myotube stage of differentiation. The medium was changed
to MEMa, 1% BSA, P/S, without serum 12 h before insulin
stimulation. As a model of insulin-resistance, muscle cells
were treated for 48 h with 500 mM palmitate. The cells
incubated with EPO (10 U/ml final concentration) or
palmitate were stimulated with 0, 10, and 100 nM insulin
for 5 min. In the different experiments, cells were incubated
with EPO for 5 min, 15 min, or 48 h. The cells were then
washed twice in ice-cold phosphoproteinbuffer (20 mMTris,
pH 7.4, 150 mM NaCl, 5 mM EDTA, 150 mM NaF, 2 mM
Na3VO4, and 10 mM pyrophosphate) and lysed (lysis buffer:
100 ml 0.5 mM phenylmethylsulfonyl fluoride (PMSF), pro-
tease inhibitor, and 1% Triton X-100 in protein buffer). The
cell lysates were centrifuged for 10 min at 4 8C. The soluble
fraction was collected and suspended in 100 ml of a Laemmli
buffer/b-mercaptoethanol mixture and stored atK20 8C.Glycogen synthesis
Glycogen synthesis was measured using a modified version
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for 24 h, and then serum starved for 4 h. After stimulation
with insulin at 0 or 120 nM for 30 min, cells were
supplemented with D-[U-14C]-glucose for 90 min and
lysed in 0.03% SDS. Carrier glycogen (20 mg/ml) was
added and the glycogen pellet was precipitated using
98% ethanol. The samples were frozen at K20 8C over-
night. The pellet was then resuspended in 300 ml water and
again incubated overnight at room temperature. Glucose
14C was counted with a liquid scintillation counter (Hidex
300SL, Hidex, Turku, Finland).2-Deoxyglucose uptake
Fully differentiated L6 myotubes were serum-starved in
DMEM supplemented with 0.1% FBS for 2 h. The cells were
then washed with Krebs–Ringer phosphate buffer (10 mM
phosphate buffer, pH 7.4, 1 mM MgSO4, 1 mM CaCl2,
136 mM NaCl, and 4.7 mM KCl) and incubated without
or with insulin (100 nM) for 20 min in the presence of
Krebs–Ringer phosphate buffer supplemented with 0.1%
BSA. Glucose transport was determined by the addition
of 2-[3H]deoxyglucose (0.1 mM and 0.5 mCi/ml). The
reaction was stopped after 5 min by aspiration, and cells
were washed four times with ice-cold PBS. The cells were
lysed in Krebs–Ringer phosphate, 1% Triton X-100, and
glucose uptake was assessed by scintillation counting.
Results were normalized for protein amount, which was
measured by bicinchoninic acid (BCA) assay.Animal studies and experimental procedures
The University of Sydney Ethics Committee (C42/
1-2009/2/4921 and C42/1-2009/3/4921) approved all
animal experiments. All procedures complied with the
Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes and the NSW Animal
Research Act. Six-week-old male Sprague–Dawley rats were
ordered from the Animal Resource Center (Canning Vale,
WA, Australia). The animals were fed either a standard diet
(16% energy from fat, 59% from carbohydrates,
2.6 kcal/kg, Rat and Mouse Breeder Food, Gordon’s
Specialty Stock Feeds (Yanderra, NSW, Australia)) or
high-fat diet (HFD) (SF03-020, 45% energy from fat, 40%
from carbohydrates, 4.78 kcal/kg, Gordon’s Specialty
Stock Feeds). Acute AKT activation was measured in soleus
muscle in a cohort of 16 adult (13-weeks-old) male rats fed
standard diet. After 4-h fasting, animals received injec-
tions of high doses of EPO (i.p., 1300 U/kg) in order
to optimize potential activation of target pathwayshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
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Printed in Great Britain(Christensen et al. 2012). The tissues were collected 60,
90, and 180 min following injection, snap–frozen in liquid
nitrogen and stored at K80 8C until analysis was
performed. Blood glucose levels were measured in a
separate cohort of adult rats.
The effect of chronic EPO treatment in animals was
investigated in 56 adult male rats. After a 1-week
acclimatization to the animal house, the animals were fed
either standard diet (CTL) or HFD for six and a half weeks.
During the last 2 weeks, animals from each diet group were
randomly assigned to receive i.p. injections of either
vehicle (saline, CTL, and HFD groups) or EPO (500 U/kg
EPO, three times a week, EPO or HFD/EPO groups). Food
and caloric intake per 24 h was monitored throughout the
duration of the study. After 2 weeks of EPO treatment, and
48 h after the sixth EPO injection, an intraperitoneal
glucose tolerance test (IPGTT, 2 g/kg glucose) was per-
formed under fasting conditions and blood was collected
from the tail vein for glucose and insulin analysis. The
glucose–insulin index was calculated as previously
reported (Marchionne et al. 2012). The animals were
returned to their cage and received the final EPO injection.
Two days later, after an overnight fast, animals were
assigned to a nonstimulated (INSK) or insulin-stimulated
(INSC) condition (1 U insulin i.p./kg body weight).
Soleus and extensor digitorum longus (EDL) muscles were
collected 10 min after injection. In both acute and
chronic EPO treatment studies, animals were killed by a
lethal injection of Lethabarb (325 mg/ml pentobarbitone
sodium) followed by surgical removal of the heart.Western blotting analysis
The cell lysates and tissue samples were analyzed by
western blotting as described previously (Barre`s et al.
2009). Briefly, the tissues were homogenized in a 10:1
(volume-to-weight) ratio of ice-cold extraction buffer
(10 mM Tris–HCl (pH 7.4); 100 mM NaCl; 1 mM each of
EDTA, EGTA, NaF, and PMSF; 2 mM Na3VO4; 20 mM
Na4P2O7; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5%
deoxycholate; and 10 mg/ml protease inhibitor cocktail).
Solubilized proteins were suspended in Laemmli buffer,
heated for 5 min at 95 8C or 20 min at 65 8C (for phospho-
rylated proteins). Proteins (20–90 mg) were separated by
SDS–PAGE and transferred onto nitrocellulose membranes.
The membranes were blocked, washed, and incubated
overnight at 4 8C with primary antibody (P-AKT and total
AKT 1/2000 in TBST 5% BSA; HSP72, 1/2000 1% milk).
Following incubation with HRP-conjugated secondary
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ChemiDoc XRSC and Image Lab Software (Bio-Rad).RNA extraction and RT-PCR
RNA extraction and RT-PCR was performed using a
modified version of a previously described method (Barre`s
et al. 2012). In brief, RNA from rat bone marrow, rat
skeletal muscle, and L6 cells was purified using TRIzol
reagent according to the recommendations of the manu-
facturer. cDNA synthesis was performed using the iScript
cDNA Synthesis Kit (Bio-Rad). PCR was performed in a
final volume of 10 ml, consisting of diluted cDNA, SYBR
Green PCR Master Mix, EPO receptor (EPOR) primer, and
nuclease-free water. The samples were analyzed in
triplicates. The primers were designed using Primer3
as follows: sense, AGGTGGACGTGTCAGCAGGC and
antisense, CCCCGCAGGTTGCTCAGGAC.Oxidative stress
F2-isoprostanes (F2-IsoPs) and isofurans (IsoFs), formed in
vivo by free radical nonenzymatic oxidation of arachidonic
acid (C20:4n-6), were quantified (Morrow et al. 1990,
Henriksen et al. 2011). F2-IsoPs and IsoFs in soleus muscle
were measured by gas chromatography–mass spec-
trometry using electron-capture negative ionization as
previously described (Mas et al. 2011).Statistical analyses
The results are presented as meanGS.D. All data were tested
for normality and equality of variance. Data derived from
western blots in the acute EPO studies were analyzed using
a one-way ANOVA. The HFD and chronic EPO animal
studies were analyzed with a two-way ANOVA (diet!EPO)





























































EPO activates AKT phosphorylation in rat soleus muscle. (A) Quantification
of P-AKT/total AKT in soleus muscle following acute i.p. injection of 1300 IU
EPO/kg (nZ4) and (B) western blot images. (C) Blood glucose time course
following i.p. injection of 1300 IU EPO/kg (nZ4). (D) Quantification of
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Printed in Great Britainanalyzed (CTL, HFD, and HFD/EPO). Insulin stimulation
in vivowas analyzed with a two-way ANOVA (ins!groups).
Following ANOVA, post hoc analysis was performed using
the Bonferroni’s test for multiple comparisons. For cell
culture experiments, a two-way ANOVA (insulin!EPO)
was used for analysis of AKT activation following
incubation with insulin and EPO once data were
normalized via appropriate transformation. Nonpara-
metric (Kruskal–Wallis or Wilcoxon–Mann–Whitney U)
tests were used for palmitate, glycogen synthesis, and
glucose uptake experiments. The correlations were
investigated using the Pearson’s product-moment
coefficient. The significance level for all comparisons was
set at P!0.05. The statistical analysis was conducted with
SPSS (IBM).Results
Acute and chronic EPO injection in lean animals is
associated with an increased phosphorylation of AKT
in muscle
We tested the effect of EPO on the activation of glucose
metabolism in skeletal muscle by measuring the phos-
phorylation of AKT, a signaling node in the metabolic
action of insulin. After an acute i.p. injection of EPO,
AKT phosphorylation at serine 473 was elevated in
soleus muscle with peak activation at 90 min (T0 vs
90 min: tZK2.806, P!0.05; Fig. 1A and B). Despite
enhanced phosphorylation of AKT in skeletal muscle,
acute EPO did not affect glycemia within a 90 min period
following injection (Fig. 1C), indicating that EPO-induced
AKT signaling activation in vivo in skeletal muscle is not
sufficient to alter whole-body glucose homeostasis. Treat-
ment of lean animals with EPO for 2 weeks also resulted in
increased basal AKT phosphorylation in soleus (tZK2.21,
PZ0.045; Fig. 1D and E).D E
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P-AKT/total AKT following chronic EPO treatment (500 U/kg, three times a
week for 2 weeks) in chow-fed animals (nZ8) and (E) western blot images.
*P!0.05 indicates a statistically significant difference between groups.
Published by Bioscientifica Ltd
Table 1 Parameters assessed in this study
CTL EPO HFD HFD/EPO
Animal characteristics at the start of
EPO treatment
nZ16 nZ16
Body weight week 4 (g) 336G24 392G35*
FBG (mM) 5.59G0.65 6.48G0.47*
Animal characteristics at the end
of the study
nZ8 nZ8 nZ8 nZ8
Body weight (g) 367G14 377G44 464G34† 466G49†
TNFa (pg/ml) 0.70G0.67‡ 0.77G0.67‡ 2.03G0.53† 1.06G0.67‡
Hct (%) 49.2G1.2 67.9G2.5† 47.3G1.2 61.9G1.9†,‡
TGs (mM) 0.29G0.11‡ 0.29G0.08‡ 0.43G0.20† 0.43G0.16†
Total cholesterol (mg/dl) 69.0G13.7 48.4G17.2‡ 75.6G11.2 59.6G15.1‡
FBG, fasting blood glucose; Hct, hematocrit; TGs, triglycerides; TNFa, tumor necrosis factor alpha; CTL, control, chow-fed treated with saline; HFD, high-fat
diet treated with saline; EPO, chow-fed treated with erythropoietin; HFD/EPO, HFD treated with EPO. Statistical analysis was conducted using a two-way
ANOVA (Diet!EPO). A Bonferroni correction was used for multiple comparisons and specific effects between groups. Animal characteristics at the start of
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225 :2 81EPO improves glucose tolerance and partially
restores insulin-stimulated AKT phosphorylation
in high-fat-fed rats
The activation of AKT signaling following injection of EPO
prompted us to determine the effect of repeated EPO
treatment on glucose metabolism. Lean and diet-induced-
obese rats were chronically treated with EPO for 2 weeks.
We controlled for the fact that, at initiation of the EPO
treatment, animals fed HFD were bigger than chow-fed
animals and exhibited signs of impaired glucose meta-
bolism, as shown by higher blood glucose (P!0.05;
Table 1). At the completion of the study, the 6-week
HFD resulted in increased fasting insulin and glucose
levels (P!0.05; Fig. 2A and B). EPO lowered fasting blood
glucose in HFD/EPO animals (diet!EPO interaction:
F(1,32)Z6.1, P!0.05; Fig. 2A) compared with HFD,
while serum insulin levels were not significantly affected
(diet!EPO interaction: F(1,28)Z2.1, PZ0.15; Fig. 2B).
Animals fed with a HFD and treated with EPO also showed
improved glycemic control as indicated by reduced blood
glucose levels during an IPGTT (F(1,28)Z3.09, PZ0.040;
Fig. 2C) with a significant difference between HFD and
HFD/EPO at 15 min. Glucose area under the curve (AUC;
Fig. 2D) was increased in the HFD group and normalized
in the HFD/EPO group, while insulin AUC increased with
HFD and was unchanged by EPO treatment (Fig. 2E).
Accordingly, the glucose–insulin index was increased in
the HFD group and reduced in the HFD/EPO group
(P!0.05; Fig. 2F).
Energy intake was similar during the course of the
study (Fig. 3A). Chronic EPO injection did not modify
weight gain or fat accumulation in EPO or HFD/EPO ratshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
 2015 The authors
Printed in Great Britaincompared with CTL and HFD respectively, as measured by
body or retroperitoneal fat pad weights (Fig. 3B and C).
These results indicate that EPO ameliorates glucose
metabolism independently from changes in body weight
or retroperitoneal fat mass. While circulating TGs were
unchanged, total-cholesterol levels were decreased after
EPO treatment (Table 1).
To determine if EPO treatment ameliorated insulin-
sensitivity in skeletal muscle, we injected insulin into
fasting CTL, HFD, and HFD/EPO animals and assessed AKT
phosphorylation in oxidative and glycolytic muscles.
In soleus, there was an interaction between insulin and
treatment groups (F(1,46)Z3.60, PZ0.045; Fig. 4A and B).
Insulin markedly stimulated AKT phosphorylation in
CTL (tZK4.76, P!0.01), while HFD inhibited its action
(Fig. 4A and B). Although EPO treatment restored insulin-
stimulated AKT phosphorylation in HFD/EPO compared
with CTL, we did not find a significant difference
compared with baseline level (InsK versus InsC,
PO0.05). Increased baseline levels of P-AKT in this group
could explain this result (Fig. 4A). In EDL, insulin-induced
AKT phosphorylation was inhibited in HFD, yet EPO did
not restore insulin signaling (PO0.05; Fig. 4C and D).EPO treatment is associated with reduced inflammation,
and oxidative stress, and increases HSP72 expression
To determine the potential contributors of EPO-induced
amelioration of glucose metabolism or AKT phosphory-
lation in muscle, we investigated the effect of chronic
EPOoninflammation levels, oxidativestress, andexpression
of HSP72, a chaperone protein known to protect insulin
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Short-term EPO treatment improves glucose metabolism. (A) Blood glucose
levels and (B) serum insulin concentrations in treatment groups. (C) Blood
glucose during an intraperitoneal glucose tolerance test (IPGTT). (D) Blood
glucose area under the curve (AUC). (E) Serum insulin AUC and (F) glucose–
insulin index during IPGTT. *P!0.05 indicates a statistically significant
difference between CTL and HFD shown in C or between groups as shown
in figures for other panels. #P!0.05 between HFD and HFD/EPO in C and
**P!0.01 indicates a statistically significant difference between groups.
CTL, control and saline; EPO, control and EPO; HFD, high-fat diet and saline;
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225 :2 82inflammatory cytokine TNFa were increased with HFD and
reduced with EPO treatment (diet!EPO interaction:
F(1,26)Z5.54, PZ0.026, with a significantly lower levels in
HFD/EPO compared with HFD; Table 1), indicating that EPO
may participate in the decrease in systemic inflammation.
To determine the role of EPO in oxidative stress in our
model of HFD-induced glucose intolerance, we quantified
both F2-IsoPs and IsoFs levels in muscle. Measurement of
F2-IsoPs or IsoFs is a state-of-the-art approach for assessing
oxidative stress in vivo in diverse disorders including obesity
(Montuschi et al. 2004). EPO treatment decreased oxidative
stress in soleus muscle as indicated by decreased IsoFs levels
in the HFD/EPO group compared with HFD (P!0.05;
Fig. 5A). The same trend was observed for F2-IsoP without
reaching significance (Fig. 5B). We also showed that EPO
treatment rescued the HFD-induced reduction in HSP72
expression in soleus (F(1,26)Z4.98, PZ0.035, HFD lower
than all other groups, P!0.05; Fig. 5C and D).EPO does not directly target AKT phosphorylation in
muscle cells
We aimed to determine if EPOR was expressed in
muscle cells and whether it could mediate metabolichttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
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Printed in Great Britainaction in vivo and in vitro. While we could not detect
EPOR in soleus or EDL muscles, we found that EPOR
was expressed at substantial levels in L6 myoblasts and
myotubes (Fig. 6A). We then demonstrated that EPO
had no significant effect on glucose uptake or glycogen
synthesis in L6 myotubes incubated with EPO alone or
co-incubated with EPO and insulin (PO0.05; Fig. 6B and C).
Given the previous results indicating that EPO activates
the PI3K/AKT pathway in metabolic cells (Mikola´s et al.
2012), we investigated the effect of EPO on AKT
phosphorylation in differentiated rat muscle cell lines
and human primary cells. We then first confirmed the
existence of a synergy between EPO and insulin towards
AKT phosphorylation using 3T3-L1 adipocytes treated
with insulin and EPO (P!0.05; Fig. 7A and B). We then
showed that EPO alone did not activate AKT in L6
myotubes acutely or chronically incubated with 10 U/ml
EPO. When cells were stimulated with submaximal or
maximal doses of insulin, EPO did not affect insulin-
stimulated AKT phosphorylation (Fig. 7C and D).
However, EPO did improve AKT phosphorylation in rat
myotubes exposed to palmitate (Fig. 7E and F). We also
showed that, in human primary myotubes, EPO did not




















































































Chronic EPO treatment partially restores insulin-stimulated AKT phos-
phorylation in soleus muscle. Quantification and western blotting images
showing P-AKT/total AKT in nonstimulated (InsK) or in insulin-stimulated
(InsC) conditions in (A and B) soleus and (C and D) EDL muscles. P-AKT/total
AKT is expressed as fold of the value for the control nonstimulated
condition. *P!0.05 indicates a statistically significant difference between
conditions. CTL, control and saline; EPO, control and EPO; HFD, high-fat

















































































Short-term EPO treatment does not alter body weight gain or fat tissue
mass. (A) Energy intake and (B) body weight during the course of the study.
(C) Retroperitoneal fat pad mass at the end of the study. Statistical
significance: *P!0.05 between chow- or HFD-fed animals and **P!0.01
between groups. CTL, chow and saline; EPO, chow and EPO; HFD, high fat
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225 :2 83P-AKT levels (Fig. 7G and H). Taken together,
these results provide evidence that while EPOR is
expressed in rat myotubes, EPO does not directly poten-
tiate insulin action in muscle cells in vitro. However,
EPO can rescue palmitate-induced inhibition of AKT
activation, indicating that specific pathway activated
by palmitate might have played a role. As EPOR washttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
 2015 The authors
Printed in Great Britainnot detectable in soleus, our results also indicate
that changes observed in vivo in soleus from EPO-
treated animals resulted from an indirect action of EPO
on this tissue.Published by Bioscientifica Ltd
































































Chronic EPO reduces oxidative stress and restores HSP72 levels in soleus
muscle. (A) Oxidative stress assessed by measurement of IsoFs and
(B) F2-IsoP levels in soleus muscle. (C) Quantification of HSP72 protein level.
(D) Representative western blot image. *P!0.05 indicates a statistically
significant difference between groups. CTL, control and saline; EPO, control
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225 :2 84Discussion
We report that EPO treatment improves glucose tolerance
in diet-induced-glucose-intolerant rats. We further show
that EPO modulates AKT phosphorylation in soleus, and
provide evidence that EPO does not directly target the
muscle cell to trigger this effect. We observed that EPO
treatment is associated with a reduced systemic inflam-
mation, lowered muscle oxidative stress, and increased
muscle HSP72 expression, indicating that the improve-
ment in glucose metabolism induced by EPO results from
the amelioration of systemic factors.
Both acute and chronic EPO treatment in vivo led to AKT
activation in soleus muscle from lean animals. A single
injection of a high dose of EPO induced transient
phosphorylation of AKT without altering systemic levels of
glucose, indicating that EPO-induced phosphorylation of
AKT in skeletal muscle has a limited role in acute glucose
control in animals with normal blood glucose levels. In
contrast, results described in a previous report indicated that
acute EPO injection in streptozotocin-induced diabetic rats






























































































While EPOR is expressed in muscle cells, EPO does not stimulate glucose
uptake or glycogen synthesis in cultured myotubes. (A) EPOR expression in
bone marrow, muscle (soleus and EDL), myoblasts, and myotubes.
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levels; however, the tissues involved have not been
identified (Mikola´s et al. 2012). Initial blood glucose levels
may thus be critical in the acute effect of EPO, consistent
with the study reporting that hyperglycemia is necessary for
stimulation of EPO-induced glucose uptake in adipocytes
(Mikola´s et al. 2012). As we have also shown that rat soleus
muscle did not express EPOR, AKT activation in our model is
likely to be indirect via a still unknown mechanism (Wang
et al. 2014). In human, acute i.v. injection of EPO was
without effect on phosphorylation of AKT, AMP-activated
protein kinase, or acetyl Co-A carboxylase, while insulin
sensitivity and blood glucose levels were not affected
(Christensen et al. 2012). The absence of AKT activation
following acute EPO injection in that study may be due to
the use of a much lower dose of EPO (200 and 400 IU/kg
versus 1300 IU/kg in the current study), to the timing of the
collection of muscle biopsies, to the fiber type composition
of the muscle analyzed, or species-specific differences.
In our study, high-fat-fed animals presented increased
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(B) Insulin-stimulated glycogen synthesis and (C) glucose uptake in L6
myotubes incubated with or without EPO. *P!0.05 indicates a statistically
significant difference between groups. NS, nonsignificant.
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EPO does not activate AKT phosphorylation in cultured myotubes.
(A) Quantifications and (B) representative western blot of P-AKT in
response to insulin in 3T3L1 adipocytes under control or EPO-treated
conditions for 48 h (nZ3). (C) Quantifications and (D) representative
western blot of P-AKT/total AKT in response to insulin in L6 myotubes
incubated under control or EPO-treated conditions for 5 min, 15 min, or
48 h (nZ4). (E) Quantification and (F) representative western blot image of
P-AKT/total AKT in response to insulin in L6 myotubes incubated with EPO,
palmitate, or EPO/palmitate. (G) Quantifications and (H) representative
western blot image of P-AKT/total AKT in response to 0 or 1 nM insulin in
human primary myotubes incubated with or without EPO (nZ3). *P!0.05
between conditions as shown on figure. EPO5, EPO15, and EPO48:
incubation with EPO for 5 min, 15 min, or 48 h respectively. Palm,
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glucose tolerance. It is noteworthy that while EPO
treatment improved glucose control, it did not change
body weight and retroperitoneal fat mass. This indicates
that EPO ameliorates glucose metabolism independently
from changes in body composition. Such effect can be
explained via direct action on metabolic tissues, or
indirectly through EPO anti-inflammatory effects (Li
et al. 2006, Alnaeeli et al. 2014). Partial recovery of glucose
tolerance was accompanied by recovery of baseline
glucose levels in the HFD/EPO group while insulin levels
were not yet affected. It is tempting to speculate that we
observed early adaptations, and that longer EPO treatment
or larger doses may be necessary to normalize insulin
levels and to restore normal glucose metabolism (Katz
et al. 2010). Our results also indicated that EPO treatment
restored insulin-stimulated AKT activation in skeletal
muscles in response to insulin in the HFD/EPO group in
oxidative muscle (soleus); however, this did not lead to a
statistically significant increase in P-AKT levels when
compared with HFD due to increased baseline levels in
this group. In contrast, EDL, a muscle characterized by
glycolytic metabolism, did not show any response to EPO
treatment. As EPOR mRNA was undetectable in soleus or
EDL, we conclude that any effect of EPO treatment on
muscle AKT phosphorylation is indirect and results from
lower systemic inflammation, reduced muscle oxidative
stress, or increased HSP72 expression, all known tohttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
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Printed in Great Britainpositively influence insulin signaling. On the other
hand, other metabolic tissues, such as liver (Meng et al.
2013) or adipose tissue (Mikola´s et al. 2012, Wang et al.
2013), which have been shown to express EPOR and
respond to EPO, can also participate in improved glucose
control in our model.
Our results from cultured cells confirm that EPO can
stimulate AKT activation in synergy with insulin in 3T3L1
adipocytes and demonstrate the lack of direct action of
EPO on muscle cells. Indeed, we show that EPO did not
affect AKT phosphorylation when rat L6 or human
primary myotubes were incubated with EPO or co-
incubated with both EPO and insulin, indicating that
EPO did not directly target AKT in differentiated skeletal
muscle cells. In agreement with the lack of effect of EPO
on AKT activation in myotubes, we also demonstrate that
EPO did not increase glucose uptake or glycogen synthesis.
However, we showed that EPO had the potential to rescue
AKT phosphorylation when cells were subjected to
palmitate treatment, a model used to mimic in vitro
the deleterious effect of HFD on insulin signaling. While
the underlying mechanism cannot be determined from
our results, these indicate that EPO signaling in myotubes
may provide some protection to the insulin signaling
cascade. Expression of the EPOR gene has been long
thought to be restricted to the erythroid lineage but has
since been identified in C2C12 myoblasts (Ogilvie et al.
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225 :2 86(Joshi et al. 2011, Jia et al. 2012), as well as in rat (Rotter
et al. 2008) and human skeletal muscle (Lundby et al. 2008,
Rundqvist et al. 2009). Although chronic treatment with
EPO in vivo resulted in increased AKT activation (Hojman
et al. 2009) and enhanced mitochondrial oxidative
phosphorylation (Plenge et al. 2012) in mouse and
human skeletal muscle respectively, it is still unclear
whether EPOR is functional and leads to a direct effect of
EPO in muscle cells. Our investigation revealed expression
of EPOR mRNA in rat L6 myotubes, although to a lesser
extent than that in myoblasts, while soleus and EDL
muscles displayed virtually no expression. Taken together,
these results indicate that EPO does not directly modulate
AKT activation in rat soleus muscle.
The mechanisms that contribute to the improvement of
glucose tolerance and muscle insulin signaling in HFD/EPO-
treated animals may also include decreased systemic
inflammation, as indicated by reduced TNFa levels, the
lower muscle oxidative stress, and enhanced expression of
chaperone protein HSP72 observed in muscles from high-
fat-fed EPO-treated animals. TNFa, which is produced by
inflamed adipose tissue, is one of the pro-inflammatory
cytokines involved in obesity-associated low grade inflam-
mation (Shoelson et al. 2006). Its effect on insulin sensitivity
and insulin signaling pathway activation in skeletal muscle
is well documented (Plomgaard et al. 2005, Hotamisligil
2006). While other pro-inflammatory cytokines such as IL6
or IL1b (Li et al. 2008) could be involved, the reduced plasma
TNFa levels observed in this study indicate that EPO
improves insulin signaling and glucose tolerance through,
at least in part, lowering of TNFa levels. In our study model,
lower TNFa levels may be associated with reduced macro-
phage infiltration in adipose tissue as previously reported
(Alnaeeli et al. 2014). It has been reported that EPO can
attenuate plasma TNFa in hemodialyzed patients (Rasic-
Milutinovic et al. 2008), and hamper TNFa production
by 3T3L1 adipocytes (Pan et al. 2013). In mice fed a HFD,
a 2-week EPO treatment has been reported to reduce
inflammation and modulate PI3K/AKT signaling in liver
(Meng et al. 2013). This indicates that EPO lowers
HFD-associated inflammation and that additional tissues
may play a role in improving glucose regulation in our
model. In addition, EPO treatment of HFD animals
decreased oxidative stress, as indicated by reduced levels of
IsoFs, and also increased HSP72 expression in soleus muscle.
The modulation of oxidative stress and the restoration of
HSP72 could both mediate the protective effect of EPO
against lipotoxicity. The expression of HSP72 is decreased
in obesity (Chung et al. 2008, Gupte et al. 2009) or T2D
(Bruce et al. 2003) and associated with insulin resistance.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-15-0010
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Printed in Great BritainConversely, overexpression or restoration of this
protein improves insulin sensitivity (Chung et al. 2008,
Gupte et al. 2009). The mechanisms involved in the reduced
expression of HSP72 in skeletal muscle in T2D are still
unclear, but seem to be driven by a systemic inflammatory
state (Chung et al. 2008).
In conclusion, we show that a 2-week EPO treatment
in rats fed a HFD can improve glucose tolerance
independently of body weight and retroperitoneal fat
content. We observed incomplete restoration of insulin-
stimulated AKT activation in muscle in vivo; however,
given the absence of EPOR expression in rat soleus and
EDL muscles and the absence of AKT activation in
myotubes exposed to EPO, we conclude that EPO does
not target AKT directly in skeletal muscle. The observed
reduced systemic TNFa level, and oxidative stress, as well
as the restoration of HSP72 expression in soleus may act in
synergy to provide protection against the diet-induced
insulin resistance in metabolic tissues and contribute to
the positive action of EPO on glucose homeostasis.Declaration of interest
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